

Regeus to Enter Into a R&D Agreement with Applied Biology To Advance Its Prostaglandin Program for Androgenetic Alopecia

Regeus to Enter Into a Research and Development Agreement with Applied Biology To Advance Its Prostaglandin Program for Androgenetic Alopecia

IRVINE, CA, UNITED STATES, May 26, 2020 /EINPresswire.com/ -- IN A BID TO ADVANCE ITS NOVEL PROSTAGLANDIN RP-001, REGEUS TO COMMENCE A STUDY FOR THE TREATMENT OF ANDROGENETIC ALOPECIA

Regeus' propriety prostaglandin GUR-701 demonstrated initial clinical safety and efficacy in a small open labeled study for androgenetic alopecia (AGA). Prior prostaglandin studies in AGA failed to demonstrate superior clinical efficacy compared to topical minoxidil.

According to Regeus COO, Igor Teterin: "Regeus' propriety prostaglandin GUR-701 overcomes many of the challenges of prior prostaglandin attempts. We are excited to commence a study to assess the efficacy and safety of GUR-701 in androgenetic alopecia."

ABOUT APPLIED BIOLOGY

Founded in 2003, Applied Biology, Inc. (www.appliedbiology.com), headquartered in Irvine, California, is a biotechnology company specializing in hair and skin science. Applied Biology develops breakthrough drugs and medical devices for the treatment of androgen mediated dermatological conditions. Applied Biology's R&D pipeline includes a topically applied prophylactic treatment for chemotherapy induced alopecia; a novel diagnostic device that can aid dermatologists in identifying non-responders to topical minoxidil; an adjuvant therapy for non-responders to topical minoxidil; and a novel therapy for female pattern hair loss.

ABOUT REGEUS

Regeus (derives from "regeneration") is a biotech company, division of Gurus BioPharm. Both companies are based at the Skolkovo Innovative Center in Moscow, Russia. Regeus develops and markets proprietary hair products. Gurus BioPharm is a world leader in the development of therapeutics based on proprietary prostaglandins.

www.gurus.bio

Monica Naegle
Applied Biology, Inc.

+1 949-387-4526

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/517926148>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.